This article is part of the supplement: Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference

Open Access Open Badges Review

Intranasal administration of acetylcholinesterase inhibitors

Henry R Costantino*, Alexis Kays Leonard, Gordon Brandt, Paul H Johnson and Steven C Quay

Author affiliations

Nastech Pharmaceutical Company Inc., 3830 Monte Villa Parkway, Bothell, Washington 98021, USA

For all author emails, please log on.

Citation and License

BMC Neuroscience 2008, 9(Suppl 3):S6  doi:10.1186/1471-2202-9-S3-S6

Published: 10 December 2008


This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeutically viable formulation. In vivo testing confirmed achievement of therapeutically relevant drug levels that matched or exceeded those for oral dosing, with a dramatic reduction in undesired emetic responses. Intranasal drug delivery is an effective option for the treatment of Alzheimer's disease and other central nervous system disorders.